Hypertension

SURMOUNT-1 Trial: Tirzepatide linked to reduced BP in patients with obesity

February 6, 2024

In the Ambulatory Blood Pressure Monitoring Substudy of the international SURMOUNT-1 trial, the weight loss medication tirzepatide significantly lowered the systolic BP of nearly 600 adults who had obesity and took the medication for 36 weeks.

• The substudy included 600 patients from the SURMOUNT-1 trial, was designed to examine the effect of the dual GLP-1/GIP receptor agonist tirzepatide on BP, and was conducted from December 2019 to April 2022.
• All participants underwent 24-hour ambulatory BP monitoring at baseline and week 36.
• The cohort had a mean age of 45.5 years, mean BMI of 37.4 kg/m^2, 68.7% were female, and 66.8% were White. 
• All participants within the substudy had BP levels less than 140/90 mmHg. If they used BP medications, they were required to have been taking their BP medications for at least 3 months prior to substudy start.
• Treatment with each tirzepatide dose reduced 24-hour systolic BP at 36 weeks compared with placebo.
• Participants taking 5 mg of tirzepatide had an average systolic BP reduction of 7.4 mm Hg; participants taking 10 mg had an average systolic BP reduction of 10.6 mm Hg; and participants taking 15 mg had an average systolic BP reduction of 8.0 mm Hg.
• The BP-lowering effects of tirzepatide were evident during both day and night BP measurements.

In 2022, the FDA approved tirzepatide for prescription as a treatment for type 2 diabetes.

In late 2023, the FDA also approved it for chronic weight management for people with obesity (BMI of 30 kg/m^2 or higher) or overweight (BMI of 27-29 kg/m^2) and at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or hyperlipidemia.

Sources:

de Lemos JA, et al. (2024, February 5). Hypertension. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. https://pubmed.ncbi.nlm.nih.gov/38314555/

(2024, February 5). AHA News Room. New weight loss medication may help lower blood pressure in adults with obesity. https://newsroom.heart.org/news/new-weight-loss-medication-may-help-lower-blood-pressure-in-adults-with-obesity

Campbell, Patrick. (2024, February 5). HCP Live. New Study Finds Tirzepatide Use Lowered Blood Pressure in Patients with Obesity. https://www.hcplive.com/view/tirzepatide-use-lowered-blood-pressure-in-patients-with-obesity-study-finds